J Korean Acad Child Adolesc Psychiatry.  2017 Apr;28(2):70-83. 10.5765/jkacap.2017.28.2.70.

The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (III): Pharmacological Treatment

  • 1Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • 2Department of Psychiatry, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
  • 3Department of Psychiatry, Pusan National University School of Medicine, Busan, Korea.
  • 4Department of Psychiatry, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
  • 5Department of Psychiatry, Kyung Hee University School of Medicine, Seoul, Korea.
  • 6Department of Psychiatry, Soonchunhyang University Seoul Hospital, Seoul, Korea.
  • 7Department of Psychiatry, International St. Mary's Hospital, Catholic Kwandong University, Incheon, Korea.
  • 8Department of Psychiatry, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Korea. ntour@unitel.co.kr


The objective of this review is the revision of the Korean practice parameters for the pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) based on the change in the diagnostic system from DSM-IV-TR to DSM-5 and psychopharmacological developments. For the evidence-based approach, the authors conducted a review of the literature, including controlled clinical trials, studies of the side effects of drugs, toxicology and meta-analyses from the United States and Europe, as well as recent research conducted in Korea. The review committee composed of Korean experts on ADHD reviewed the revised parameters. This revised version reveals how to use central nervous system psychostimulants, non-stimulants such as atomoxetine and alpha2 agonists, and other medication for ADHD, and how to manage the adverse effects of such medication. At the end of this revised version, the authors propose recommendations for the pharmacotherapy of ADHD.


Attention-deficit hyperactivity disorder; Psychostimulant; Non-stimulant; Pharmacotherapy

MeSH Terms

Advisory Committees
Atomoxetine Hydrochloride
Central Nervous System
Drug Therapy
Drug-Related Side Effects and Adverse Reactions
United States
Atomoxetine Hydrochloride
Full Text Links
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr